With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?

Experts Weigh In On Positioning BMS/Bluebird’s Abecma And GSK’s Blenrep

 
• By Alaric DeArment

Market Snapshot: GSK's Blenrep and BMS's Abecma are the first of many drugs for the late-line setting. In many cases, the CAR-T may be the first choice, but some patients are unable to handle it or risk progressing while awaiting treatment.

Open Book Of prostate multiple myeloma, Conceptual Image - Image
With two BCMA-targeting myeloma therapies available, the question now is how to position them in treatment • Source: Shutterstock

More from Market Snapshot

More from Scrip